深圳国华网安科技股份有限公司第十二届董事会2025年第九次临时会议决议公告

Group 1 - The company held its 9th temporary board meeting on December 1, 2025, to discuss and approve the capital increase in Zhongshan Runle Pharmaceutical Co., Ltd. [2][3] - The board unanimously approved the proposal for the capital increase, with all five attending directors voting in favor [3][4] - The capital increase involves an investment of 1.04 million RMB, which will result in the company holding 50.9804% of Runle Pharmaceutical's equity [8][11] Group 2 - Runle Pharmaceutical, established on January 27, 2025, has a registered capital of 1 million RMB and focuses on the sale of health food and pharmaceuticals, including a pediatric cough syrup recently granted market approval [8][9] - The capital increase will not constitute a major asset restructuring and does not require shareholder approval [8][15] - The funding for this investment will come from the company's own funds and will not affect its existing business operations [15] Group 3 - The company aims to expand its presence in the pharmaceutical sector through this investment, seeking to enhance its core competitiveness and create new revenue streams [15] - The future performance of Runle Pharmaceutical will be influenced by various factors, including policy, economic, and market conditions [15]